Stockreport

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Inc.  (CNTX) 
PDF Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in Septemb [Read more]